Apixaban in non-valvular atrial fibrillation and treatment of venous thromboembolism: universal safety advantage in different categories of patients

This review presents data on the frequency of bleeding in direct comparison of apixaban and vitamin K antagonists in the context of prospective randomized controlled trials. According to ARISTOTLE, AUGUSTUS and AMPLIFY studies, Apixaban has an advantage over vitamin K antagonists in terms of safety regardless of the indications (prevention of cardioembolic complications in nonvalvular atrial fibrillation, treatment of venous thromboembolic complications), which applies to all categories of patients studied, including those with increased risk of bleeding (elderly and old age, chronic renal failure, low body weight, arterial hypertension, the need for simultaneous use of one or two antiagregants, 3 or more points on the HAS-BLED scale). Moreover, the course of the accumulation curves of clinically significant bleedings indicates a constant increase in the number of patients who can prevent bleeding with prolonged use of apixaban instead of vitamin K antagonists.

Prospective randomized clinical trials AMPLIFY and CARAVAGGIO show that in early treatment of proximal deep vein thrombosis of the lower limbs and/or thromboembolism of pulmonary arteries in patients without malignant tumors apixaban is safer than low-molecular-weight heparin enoxaparin, In long-term treatment of venous thromboembolic complications in patients with malignant tumors is not worse in safety than low-molecular-weight heparin dalteparin. Additional evidence for the safety of apixaban was obtained by comparing it with placebo in the prolonged treatment of venous thromboembolic complications in patients with low risk of serious bleeding in a prospective randomized controlled trial AMPLIFY-EXT.

1. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europ J Cardio-Thoracic Surg. 2016;50(5):e1-e88. doi: 10.1093/ejcts/ezw313.

2. Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez B., Bounameaux H. et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.

3. Konstantinides S., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V-P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(4):543-603. doi: 10.1093/eurheartj/ehz405.

4. Granger C.B., Alexander J.H., McMurray JJ., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039.

5. Hylek E.M., Held C., Alexander J.H., Lopes R.D., De Caterina R., Woidyla D.M. et al. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. JACC. 2014;63(20):2141-2147. doi: 10.1016/j.jacc.2014.02.549.

6. Hohnloser S.H., Hijazi Z., Thomas L., Alexander J.H., Amerena J., Hanna M. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830. doi: 10.1093/eurheartj/ehs274.

7. Lopes R.D., Al-Khatib S.M., Wallentin L., Yang H., Ansell J., Bahit M.C. et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012;380(9855):1749-1758. doi: 10.1016/S0140-6736(12)60986-6.

8. Wallentin L., Lopes R.D., Hanna M., Thomas L., Hellkamp A., Nepal S. et al. Efficacy and safety of apixaban compared with warfarin in different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2013:127(22):2166-2176. doi: 10.1161/CIRCULATIONAHA.112.142158.

9. Focks JJ., Brouwer M.A., Wojdyla D.M., Thomas L., Lopes R.D., Washam J.B. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. doi: 10.1136/bmj.i2868.

10. Rao M.P., Vinereanu D., Wojdyla D.M., Alexander J.H., Atar D., Hylek E.M. et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights from the ARISTOTLE Trial. Am J Med. 2018;131(3):269-275. doi: 10.1016/j.amjmed.2017.10.036.

11. Alexander J.H., Andersson U., Lopes R.D., Hijazi Z., Hohnloser S.H., Ezekowitz J.A. et al. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016;1(6):673-681. doi: 10.1001/jamacardio.2016.1829.

12. Bahit M.C., Lopes R.D., Wojdyla D.M., Held C., Hanna M., Vinereanu D. et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017;103(8):623-628. doi: 10.1136/heartjnl-2016-309901.

13. Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-1524. doi: 10.1056/NEJMoa1817083.

14. Windecker S., Lopes R.D., Massaro T., Jones-Burton C., Granger C.B., Aronson R. et al. Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation. 2019;140(23):1921-1932. doi: 10.1161/CIRCULATIONAHA.119.043308.

15. Vora A.N., Alexander J.H., Wojdyla D., Aronson R., Granger C.B., Darius H. et al. Hospitalization among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated with Apixaban or Aspirin. Circulation. 2019;140(23):1960-1963. doi: 10.1161/CIRCULATIONAHA.119.043754.

16. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M. et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013;369:799-808. doi: 10.1056/NEJMoa1302507.

17. Raskob G.E., Gallus A.S., Sanders P., Thompson J.R., Agnelli G., Buller H.R. et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thromb Haemost. 2016;115(04):809-816. doi: 10.1160AH15-09-0752.

18. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M. et al. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013;368:699-708. doi: 10.1056/NEJMoa1207541.

19. Agnelli G., Becattini C., Meyer G., Munoz A., Huisman M.V., Connors J.M. et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382:1599-1607. doi: 10.1056/NEJMoa1915103.